PhaseRx, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2016. The net loss for the quarter ended December 31, 2016 was $3.5 million, or $0.30 per basic and diluted share, compared to a net loss of $2.3 million, or $4.25 per basic and diluted share, for the quarter ended December 31, 2015. Loss from operations was $3.3 million compared with $1.7 million a year ago. The net loss for the year ended December 31, 2016 was $20.1 million, or $2.68 per basic and diluted share, compared to $7.4 million, or $14.22 per basic and diluted share for 2015. Loss from operations was $18.3 million compared with $5.8 million a year ago.